#ASH24: Retrospective analysis shows potential for GLP-1s to treat blood clotsnews2024-12-10T02:08:33+00:00December 10th, 2024|Endpoints News|
Trump elevates disproven vaccines-autism link in interviewnews2024-12-09T21:01:00+00:00December 9th, 2024|Endpoints News|
Supreme Court won’t take up PhRMA-Arkansas 340B expansion casenews2024-12-09T20:44:59+00:00December 9th, 2024|Endpoints News|
Agios’ stock drops after disclosing new liver-related safety warning in filing to FDAnews2024-12-09T19:03:22+00:00December 9th, 2024|Endpoints News|
#ASH24: GSK reports Blenrep overall survival data in multiple myeloma as it plots market reentrynews2024-12-09T18:30:55+00:00December 9th, 2024|Endpoints News|
#ASH24: AbbVie, Genmab tout Epkinly combinations in earlier lines of non-Hodgkin lymphomanews2024-12-09T17:00:09+00:00December 9th, 2024|Endpoints News|
Amazon Pharmacy, Ro say they help patients stick with GLP-1 drugs longernews2024-12-09T15:31:32+00:00December 9th, 2024|Endpoints News|
Insurance executive killing puts spotlight on security measures at JP Morgan meetingnews2024-12-06T19:58:01+00:00December 6th, 2024|Endpoints News|
Merus receives FDA accelerated approval to treat NRG1+ cancersnews2024-12-05T20:51:50+00:00December 5th, 2024|Endpoints News|
Lilly continues to expand its empire of GLP-1 factories with new $3B buildoutnews2024-12-05T20:30:57+00:00December 5th, 2024|Endpoints News|
